Αρχική World News FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma World News FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Από Ogkologos - 31 Ιανουαρίου, 2025 699 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study CK-301-101 Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR 7 ways we’ve influenced progress in lung cancer 1 Νοεμβρίου, 2022 Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... 20 Μαΐου, 2020 FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable... 15 Μαρτίου, 2024 PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based... 10 Ιουλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on... EMA Recommends Extension of Therapeutic Indications for Epcoritamab Νέος βιοδείκτης για τις γυναίκες πριν την εμμηνόπαυση Artificial Intelligence Expedites Brain Tumor Diagnosis during Surgery